Activity Summary:

CAR T-cell therapies have revolutionized the treatment of several, previously incurable, refractory hematologic malignancies, including Multiple Myeloma (MM). While two CAR T-cell products are now approved and several are under investigation for MM.

During this educational presentation, Dr. Joseph Mikhael reviews important breakthroughs of CAR T-cell therapy in MM. Throughout the video he highlights the most relevant updates in CAR T-cell therapy from 2025 key studies and publications, as well as provides insights into the implications of these developments on the treatment landscape.

Activity Summary:
To further expand knowledge from the What's New Doc? End-of-the-Year Updates on IPF presented by Dr. Steven Nathan, HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Clinical Snippet Highlights
Concise, one-page summaries of key IPF studies featured in this activity, offering quick, actionable insights to support day-to-day clinical decision-making.

Downloadable Slides
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
These clinical videos and podcasts are accredited, on-demand presentations that feature experts discussing recent clinical updates, hot topics and treatment options that were presented at the annual hematology meeting December 6-9 in Orlando, FL. These activities are designed to keep healthcare professionals abreast of the most recent clinical findings.

This series of conference highlights covers leukemia, myelodysplastic syndromes (MDS), myelofibrosis (MF), as well as hemophilia A and B. Please click the links to participate in each of these activities.

Activity Summary:
A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Activity Summary:
Enhance your learning from the Hematologic Cancer Updates activity with a curated resource library built for real-world clinical needs. Access downloadable visual summaries, practical takeaways and ready-to-share content—ideal for quick reference and team-based discussions, and perfectly aligned with the podcast and highlights video.

Clinical Slide Deck: Downloadable PDF of presentation slides, including data visuals, algorithms and expert insights—ideal for review, teaching or clinical discussions.

Clinical Snippet Highlights: Concise, one-page summaries of key posters and abstracts, offering quick, actionable insights to support day-to-day clinical decision-making.

Expert Commentary Transcript: A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Despite advances in understanding PAH, several opportunities remain to further improve patient outcomes, particularly in timely diagnosis, the differentiation to other PH subtypes, treatment challenges, and the management of cardiovascular comorbidities.

During these two Clinical Snippet episodes, Dr. Oudiz highlights the latest advances in PAH that were presented at fall conferences in Seattle, WA; Chicago, IL; and Amsterdam, Netherlands in September-October 2025.

Activity Summary:

A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Activity Summary:
Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care.

Through impactful presentations, posters and abstracts, Dr. Raajit Rampal provides expert commentary on the latest advances in Leukemia, Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF) presented at the annual hematology meeting in Orlando, FL.

Activity Summary:
PH is currently divided into groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This educational slide kit presents the latest research in diagnosing and managing Group 2-5 in patients, including the distinction of specific groups – CTEPH, PH-ILD, PH-COPD, CPFE, CTD.

Activity Summary:
Novel therapies and combinations are currently under investigation for the treatment of acute myeloid leukemia (AML). These include venetoclax, FLT3 inhibitors, IDH inhibitors, menin inhibitors, antibody-drug conjugates, CAR T-cell approaches, and novel targeted agents. Similarly, a number of clinical trials are underway for other leukemias, myelodysplastic syndromes (MDS) and myelofibrosis (MF).

In this Conference Highlights accredited video, Dr. Raajit Rampal discusses the latest cutting-edge evidence in leukemia, MDS and MF, presented in Orlando, FL December 6th – 9th, integrating new evidence into personalized approaches, optimizing patient outcomes and improving the overall quality of care.

Activity Summary:
New analyses show rising prevalence of progressive pulmonary fibrosis, persistent diagnostic delays, and continued gaps in antifibrotic use. Fresh data from major trials, including nerandomilast, inhaled treprostinil, admilparant, deupirfenidone, and nalbuphine ER for chronic cough, point to meaningful advances on the horizon. At the same time, patient-centered research highlights the need for clearer communication, coordinated care, and earlier intervention to improve daily functioning and long-term outcomes.

This CME activity brings all these findings together in one clear, concise program that helps clinicians keep pace with a rapidly changing field and deliver more effective, patient-focused care.

Activity Summary:
IPF care is shifting fast, and this year brought major data that will influence how clinicians diagnose, monitor, and manage disease in the year ahead. What’s New Doc? End-Of-The-Year Updates on IPF is a focused, high-impact CME activity designed to give pulmonologists, ILD specialists, and multidisciplinary care teams a clear view of the most important 2025 findings and how they translate to practice.

This activity reviews new epidemiologic insights, real-world antifibrotic outcomes, patient-reported challenges, and the latest trial results for emerging therapies expected to shape care in 2026. Steven Nathan, MD guides learners through the evidence with practical takeaways that support better decision making on diagnosis, therapy selection, tolerability management, and quality-of-life improvement.

Activity Summary:
One of the most active areas in HIV research is ART switch strategies in virologically suppressed patients with HIV (PWH). Recent switch studies highlight the use of INSTI-, non-INSTI, and long-acting ART regimens as well as a shifting in strategies–from one of only achieving viral suppression towards also addressing simplification, minimizing long-term toxicities, managing comorbidities, and improving quality of life. This activity is designed to update healthcare professionals with the latest cutting-edge evidence on ART switch strategies in virologically suppressed PWH that were reported in 2025 as well as discuss their implications on patient management trends for 2026.

Activity Summary:
One of the most active areas in HIV research is ART switch strategies in virologically suppressed patients with HIV (PWH). Recent switch studies highlight the use of INSTI-, non-INSTI, and long-acting ART regimens as well as a shifting in strategies–from one of only achieving viral suppression towards also addressing simplification, minimizing long-term toxicities, managing comorbidities, and improving quality of life. This activity is designed to update healthcare professionals with the latest cutting-edge evidence on ART switch strategies in virologically suppressed PWH that were reported in 2025 as well as discuss their implications on patient management trends for 2026.

Activity Summary:
Methamphetamine use is a growing public health concern with serious cardiovascular consequences. One of the most challenging and underrecognized complications is methamphetamine-associated pulmonary arterial hypertension (Meth-APAH), a progressive condition with high morbidity that often presents alongside complex psychosocial and adherence issues.

This on-demand, case-based CME activity equips clinicians with the knowledge and tools to identify, evaluate, and manage Meth-APAH using an evidence-based, multidisciplinary approach.

Activity Summary:
To reinforce key insights from the Transforming ILD Management activity and support real-world application, this resource library offers downloadable materials for quick reference and team-based learning. Designed for busy clinicians, these tools include concise visual summaries, clinical takeaways, and ready-to-share content that complement the podcast and highlights video.

Available Resources:

• Clinical Snippet Highlights
  Concise, one-page summaries of key ILD posters and abstracts presented in Chicago, IL, from October 19-22, 2025, featured in this activity, offering quick, actionable insights to support day-to-day clinical decision-making.
• Interactive Q&A Summaries
  Concise summaries of expert faculty responses to key questions on ILD diagnosis and management, compiled for easy reference after the program.
• Guideline Updates
  A summary of the latest update to ILD-related guidelines to support evidence-based practice.
• References and Resource Links
  Direct access to featured studies, abstracts, and other key materials cited in the program.
• Accredited Slides
  Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.
• Expert Commentary Transcript
  A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Significant disparities in HIV acquisition risk, access to ART, and viral suppression persist in the United States between racial groups, specific populations, and geographies, among others. Long-acting ART expands existing options for HIV treatment. Further, understanding the appropriate use of ART options along with prevention and management of co-morbidities strategies are critical in the long-term management of HIV.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Pre-exposure prophylaxis (PrEP) provides safe and robust protection again HIV infection in a diversity of populations at risk. In addition, PrEP when used in combination with other approaches has led to reductions in population-level HIV incidence at regional and city levels. This activity will discuss the impact of PrEP on ending the HIV epidemic, benefits and limitations of new and future PrEP options, and strategies to improve sustainable implementation of PrEP.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Adolescents are disproportionately affected by HIV, accounting for approximately 1 in 5 new HIV infections in the United States. The expanded options for pre-exposure prophylaxis (PrEP) in adolescents provides clinicians with additional, effective tools to further reduce the risk of HIV transmission in this group. Once diagnosed, youth with HIV are the least likely out of any age group to be linked to care and achieve viral suppression once on ART.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:

COPD care is evolving - are you keeping up? In this four-part podcast series, Drs. Sonali Bose and MeiLan Han share practical insights on personalizing COPD treatment, applying the latest guideline updates, and managing complex cases of dyspnea and exacerbation. Through expert discussion and case-based learning, you’ll gain strategies to confidently navigate therapeutic decision-making and improve patient outcomes.

What You’ll Learn:

• How to apply 2025 GOLD guideline updates to your COPD practice
• Strategies for managing patients with persistent symptoms despite dual or triple therapy
• Biomarker-driven decision-making for recurrent exacerbations
• Real-world case reviews with actionable, expert commentary

Activity Summary:
Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life.

Join Dr. Bose and Dr. Han as they present key clinical findings in COPD Management. This activity includes four modules:

1. COPD Management
2. Highlights from 2025 Conferences and Publications
3. Persistent Dyspnea Despite Guideline-based Therapy (Case Review)
4. Recurrent Exacerbations in Biomarker-defined Subgroup (Case Review)

Activity Summary:
The field of pulmonary medicine, especially in the management of interstitial lung diseases (ILD), is experiencing a vibrant era of growth with continuous advancements in diagnostic methods and treatment strategies. These progresses are transforming patient care, though the rapid pace of emerging research and the complexities involved in integrating new evidence into clinical practice present unique challenges.

These accredited slides offer key presentations, posters, and abstracts presented in Chicago from October 19-22, 2025, that have important clinical implications for advancing the care of interstitial lung disease (ILD).

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with "what you need to know" podcast episodes from data presented at IDWeek 2025.

Activity Summary:

In this 15-minute podcast, Dr. Steven Nathan reviews clinically significant presentations, posters, and abstracts presented in Chicago from October 19-22, 2025, that offer key insights for improving the diagnosis and management of interstitial lung disease (ILD).